Drugs / Rexin-G
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00121745 | Jul 2005 → Jul 2007 | malignant pancreatic neoplasm | Epeius Biotechnologies | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT00505271 | Jul 2007 → Jul 2010 | breast cancer | Epeius Biotechnologies | Completed | No outcome recorded |
| Phase 1/2 | NCT00504998 | Jul 2007 → Jul 2010 | malignant pancreatic neoplasm | Epeius Biotechnologies | Completed | No outcome recorded |
| Phase 1/2 | NCT00505713 | Jul 2007 → Jul 2010 | sarcoma | Epeius Biotechnologies | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00572130 | Dec 2007 → Jul 2010 | osteosarcoma | Epeius Biotechnologies | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rexin-G | “Rexin-G is a tumor-targeted (pathotropic or disease-seeking) nanoparticle that when injected intravenously, seeks out and accumulates in cancerous lesions” NCT00505713 ↗ |
| Action | Inhibit | “Rexin-G is a tumor-targeted gene therapy vector that contains a "killer" gene that blocks the action of the human cyclin G1 gene.” NCT00121745 ↗ |
| Route | Intravenous | “Rexin-G, given intravenously” NCT00121745 ↗ |